数据与计算发展前沿 ›› 2023, Vol. 5 ›› Issue (4): 57-76.

CSTR: 32002.14.jfdc.CN10-1649/TP.2023.04.006

doi: 10.11871/jfdc.issn.2096-742X.2023.04.006

• 专刊: “基础研究”联合专刊 • 上一篇    下一篇

基于Cortellis数据库的mRNA技术研发管线分析

李东巧1,*(),王茜1,2   

  1. 1.中国科学院文献情报中心，北京 100190
    2.中国科学院大学，经济与管理学院，信息资源管理系，北京 100190
  • 收稿日期:2023-06-30 出版日期:2023-08-20 发布日期:2023-08-23
  • 通讯作者: *李东巧（E-mail: lidq@mail.las.ac.cn）
  • 作者简介:李东巧，中国科学院文献情报中心副研究员，青年创新研究员，中国科学院青年创新促进会会员。博士毕业于北京协和医学院。主要从事生物技术领域的战略情报研究，担任中国科协决策咨询专家，国家自然科学基金项目评议专家，《医学信息学杂志》等期刊审稿专家。近年来先后主持国家自然科学基金项目、科技部项目、NSTL科技管理决策咨询项目、中国科学院项目等国家及部级以上项目10余项，在国内外知名学术期刊发表论文20余篇，参与出版著作5本，发布研究报告2份，多份咨询建议被省部级以上领导及部门批示或采纳。
    负责制定论文框架，参与数据分析，论文撰写和修改。
    LI Dongqiao, is an associate researcher and Young Innovative Researcher at National Science Library, Chinese Academy of Sciences (CAS), and also a member of the Youth Innovation Promotion Association of CAS. After obtaining a doctoral degree from Peking Union Medial College, she has been mainly focusing on the strategic information research in biotechnology fields. She works as an expert for China Association for Science and Technology on decision making and consultation as well as an evaluation expert for the projects of National Natural Science Foundation of China. In addition, she takes the role of a reviewer of journals including Journal of Medical Intelligence. In recent years, she has presided over 10 projects at national or ministerial level, such as projects of National Natural Science Foundation of China, Ministry of Science and Technology, Chinese Academy of Sciences, and projects on S&T management and decision-making consultation of National Science and Technology Library. Dr. Li has published more than 20 scientific papers in both domestically and internationally well-known journals. She has also participated in the publication of five monographs and two research reports. She has submitted a good number of consultative suggestions which received written comments or were adopted by government officials and units above the provincial level.
    In this paper, she is responsible for drawing up the paper framework, participating in data analysis, paper writing and revision.
    E-mail: lidq@mail.las.ac.cn
  • 基金资助:
    中国科学院青年创新促进会资助项目(E329040901)

Study on the R&D Pipeline Analysis of mRNA Technology Based on Cortellis Database

LI Dongqiao1,*(),WANG Xi1,2   

  1. 1. National Science Library, Chinese Academy of Sciences, Beijing 100190, China
    2. Department of Information Resources Management, School of Economics and Management, University of Chinese Academy of Sciences, Beijing 100190, China
  • Received:2023-06-30 Online:2023-08-20 Published:2023-08-23

RichHTML

14

PDF

560

摘要：

【目的】本文旨在通过对mRNA技术相关药物或疫苗进行全面分析，以期为充分发挥mRNA技术潜力提供有价值的信息。【方法】基于Cortellis数据库，从发展趋势、主要国家/地区、主要机构、作用靶点、产品类型、疾病适应症、临床阶段和市场情况等多维度对mRNA技术相关药物或疫苗进行分析，力求能全面系统地反映mRNA领域研究现状。【结果】mRNA产品自2020年起呈快速发展趋势；美国、中国和德国的mRNA产品数量位列全球前三位；Moderna公司和BioNTech公司的mRNA产品数量较多；mRNA产品主要应用于传染性疾病领域、肿瘤领域和内分泌/代谢疾病领域，其靶点以冠状病毒尖峰蛋白为主；mRNA产品临床研究阶段以临床前研究阶段为主。【结论】我国已处于mRNA相关研究技术的前沿，但与美国、德国等国家相比还存在一定差距，未来我国应加大对mRNA技术领域项目部署和基础研究力度，提高临床研究水平和成果转化应用等。

关键词: mRNA, 新冠肺炎, 肿瘤, 传染病

Abstract:

[Objective] This paper aims to provide valuable information for fully utilizing the potential of mRNA technology through a comprehensive analysis of mRNA technology related drugs or vaccines. [Methods] Based on the Cortellis database, mRNA technology related drugs or vaccines were analyzed from the development trends, major countries/regions, major institutions, action targets, product types, disease indications, clinical stages and market conditions, so as to comprehensively and systematically reflect the research status in the field of mRNA. [Results] mRNA products have shown a rapid development trend since 2020. The number of mRNA products in the United States, China and Germany rank the top three in the world. Moderna and BioNTech have a large number of mRNA products. mRNA products are mainly used in the field of infectious diseases, neoplasms and endocrine/metabolic diseases, and their targets are mainly coronavirus peak protein. The clinical research of mRNA products is mainly at the preclinical research stage. [Conclusions] China has been in the forefront of mRNA related research, but there is still a gap compared with the United States, Germany and some other countries in basic research related to mRNA technologies. In the future, China should increase the project deployment and basic research in the field of mRNA technology, improve the level of clinical research and the transformation and application of research achievements.

Key words: mRNA, COVID-19, neoplasms, infectious diseases